July 1, 2021 Innovative gene-editing therapies for two significant blood disorders, beta thalassemia and sickle cell anaemia, have received a boost with the AKU’s Centre for Regenerative Medicine and Stem Cell Research, CRM, winning a competitive research grant of Rs159.60 million ($1.02 m) to look for a genetic ‘fix’. Thalassemia and sickle cell disease are genetic disorders, passed down from parent to child, and are common in Pakistan. There are as many as 100,000 transfusion-dependent thalassemia patients in the country. Every year another 5,000 babies are born with the disorder. On...